Mode
Text Size
Log in / Sign up

MRI radiomics models show moderate accuracy for predicting HER2 status in young breast cancer patientsMRI scans may help predict HER2 status in young breast cancer patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret MRI radiomics for HER2 prediction in young patients as preliminary research requiring validation.

This retrospective observational study evaluated multiparametric MRI-based radiomics for predicting HER2 expression status in 375 young breast cancer patients (age <40 years) from two medical centers. Researchers compared four predictive approaches: clinical models, conventional whole-tumor radiomics, habitat radiomics (analyzing tumor subregions), and combined models using preoperative DCE-MRI and DWI scans.

For predicting HER2 negative versus positive status (Task 1), the clinical model achieved an AUC of 0.683, the whole-tumor model 0.731, the habitat model 0.761, and the combined model 0.768 in the training cohort. For distinguishing HER2 zero from low expression (Task 2), the whole-tumor model reached AUC 0.673, habitat model 0.649, and combined model 0.758. No clinical model was developed for Task 2. Safety and tolerability data were not reported.

Key limitations include the retrospective design, reporting of only training cohort performance metrics, and absence of a clinical model for Task 2. The study demonstrates associations only, not causality. While habitat radiomics showed better discriminatory effectiveness than whole-tumor approaches for HER2 positive expression, these findings require prospective validation in broader populations before considering clinical implementation. The research suggests radiomics may eventually supplement but not replace current HER2 testing methods.

Researchers wanted to see if MRI scans could help predict HER2 protein levels in breast cancer tumors before surgery. HER2 status helps guide treatment decisions. They studied 375 young breast cancer patients under age 40 from two medical centers, using their preoperative MRI scans to build computer prediction models.

The study compared different prediction approaches. One method analyzed the entire tumor, while another looked at different areas within the tumor. The models that combined information from different tumor areas performed best at distinguishing between HER2-negative and HER2-positive tumors. For a more detailed task of separating zero HER2 from low HER2, combined models also showed the highest accuracy.

This was a retrospective study, meaning researchers looked back at existing patient data rather than testing the approach in real time. The performance numbers reported came from the training phase of the models, not from independent validation. No safety concerns were reported because this was an analysis of existing scans, not a new treatment.

Readers should understand this is early research exploring a possible future tool. The study shows MRI-based analysis might one day help predict HER2 status non-invasively in young patients, but much more research is needed before doctors could use this approach in practice.

What this means for you:
Early study suggests MRI analysis might predict HER2 status, but it's not ready for clinical use.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedMar 2026
View Original Abstract ↓
ObjectiveHabitat imaging can quantify intratumoral heterogeneity in young breast cancer patients, providing support for the prediction of HER2 expression levels. Therefore, this study aimed to compare the predictive ability of habitat models and conventional whole-tumor models for HER2 expression status in young breast cancer patients using multiparametric MRI.MethodsA retrospective cohort consisting of 375 young breast cancer patients (age < 40 years) who underwent preoperative MRI scanning at two medical centers was included in this study. Two binary classification tasks were designed: Task 1 (HER2 negative expression vs. HER2 positive expression) and Task 2 (HER2 zero expression vs. HER2 low expression). The training cohort (n=206) comprised patients from Center 1, with the external validation cohort (n=169) recruited from Center 2. Clinicopathological and MRI characteristics were collected. Radiomics features based on whole-tumor and habitat regions were extracted from DCE-MRI and DWI images, respectively. Clinical models, conventional whole-tumor models, habitat models, and combined models were constructed. Subsequently, model performance was evaluated by the AUC, sensitivity, and specificity.ResultsIn Task 1, the AUC of the clinical model, conventional whole-tumor model, habitat model, and combined model in the training cohort were 0.683, 0.731, 0.761, and 0.768 respectively. In Task 2, no clinicopathological features were determined as independent risk factors, thus no clinical model was developed. The AUC for the whole-tumor model, habitat model, and combined model in the training cohort were 0.673, 0.649, and 0.758 respectively.ConclusionThe habitat model exhibited better discriminatory effectiveness in identifying HER2 positive expression in young breast cancer patients, in comparison to the whole-tumor radiomics model. The integration of conventional whole-tumor radiomics features with habitat features and clinicopathological characteristics can enhance model performance.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.